Compare MAIR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAIR | BMRN |
|---|---|---|
| Founded | N/A | 1996 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 13.0B |
| IPO Year | 2026 | 1999 |
| Metric | MAIR | BMRN |
|---|---|---|
| Price | $25.29 | $65.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $88.22 |
| AVG Volume (30 Days) | ★ 2.8M | 1.8M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.26 | ★ 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | $96.42 | ★ $83.65 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $24.75 | $49.26 |
| 52 Week High | $41.89 | $70.98 |
| Indicator | MAIR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 51.24 |
| Support Level | N/A | $64.07 |
| Resistance Level | $33.21 | $66.28 |
| Average True Range (ATR) | 1.22 | 1.65 |
| MACD | 0.06 | -0.41 |
| Stochastic Oscillator | 8.37 | 34.95 |
Madison Air Solutions Corp is an HVAC and indoor air-quality technology company. Its segments are Commercial and Residential. It generates the majority of its revenue from the Commercial segment, which includes Commercial businesses that deliver well-engineered, custom, and semi-custom air quality systems to support process control, regulatory compliance, energy efficiency, and productivity in mission-critical environments; and the Residential segment, anchored by trusted brands like AprilAire, Broan-NuTone, Zephyr, and Others. Its geographic areas are the U.S, the Americas, Europe, and Other. The group generates the majority of its revenue from the U.S market.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.